Patients Say Ketamine Beats Years on Prozac, NY Post Reports

Patients Describe Ketamine Outperforming Years on Prozac

An exclusive New York Post report published October 15, 2026, features patients who say ketamine-based treatment helped their depression more than years spent on Prozac (fluoxetine), a widely prescribed SSRI (selective serotonin reuptake inhibitor). The report, as described in its headline and summary, centers on patient accounts rather than a new clinical trial, and the specific treatment details, dosing, and clinic settings referenced by those patients are not available in the material reviewed for this analysis.

The headline's reference to an "FDA-approved ketamine treatment" points to a detail readers should understand clearly before assuming it applies to every ketamine clinic. Esketamine, sold under the brand name Spravato, is a nasal spray the FDA approved in 2019 for treatment-resistant depression when used alongside an oral antidepressant, and later cleared for depressive symptoms with suicidal thoughts in adults. It remains, as far as this analysis can confirm, the only ketamine-derived product with that specific depression approval. Generic or compounded ketamine, delivered by IV infusion, intramuscular injection, or at-home sublingual lozenges, is prescribed off-label for depression, meaning doctors use their clinical judgment to prescribe it even though the FDA has not evaluated and approved it for that specific use.

Patient Stories Are Evidence, But Not the Same as Trial Data

Individual accounts of relief after years of ineffective SSRI treatment are meaningful and consistent with a broader pattern researchers have reported: a subset of patients with treatment-resistant depression, those who have not responded to at least two standard antidepressants, show rapid mood improvement after ketamine or esketamine treatment. That pattern is part of why esketamine earned its 2019 FDA approval in the first place.

What patient testimonials in a news feature cannot do is establish how an individual reader will respond, how durable their improvement will be, or how it compares on average to continuing an SSRI under different dosing or augmentation strategies. Depression treatment response varies by person, and head-to-head outcomes depend on factors a short feature typically does not cover, such as prior treatment history, co-occurring anxiety or substance use, and whether therapy was paired with medication. Readers should treat the Post's patient accounts as real, first-person experiences worth taking seriously, while recognizing they are not a substitute for a controlled comparison between ketamine and SSRIs.

Questions to Ask Before Starting Any Ketamine Treatment

For readers weighing ketamine after their own long run on SSRIs like Prozac, the practical decision point is less about which drug "wins" and more about matching the treatment format to proper medical oversight. A few questions help separate well-run care from a thinner offering:

Is this esketamine (Spravato) or generic ketamine? Spravato requires in-person administration at a certified healthcare setting under the FDA's REMS (Risk Evaluation and Mitigation Strategy) program, including roughly two hours of monitoring per session for sedation and dissociation. Generic ketamine, including at-home sublingual or IM options offered by many telehealth providers, does not carry that same federal monitoring mandate, so the clinic's own screening and follow-up protocol matters more.

Who is doing the medical screening? A legitimate ketamine or esketamine provider should screen for personal or family history of psychosis, uncontrolled hypertension or cardiovascular disease, and substance misuse before prescribing, and should have a licensed clinician, not just an intake form, review that history.

What does ongoing care look like? Ask whether sessions are paired with therapy or psychiatric follow-up, how dosing is adjusted over time, and what happens if symptoms do not improve after an initial course, typically three to six sessions for many ketamine protocols.

What will this cost, and is it covered? Esketamine is more likely to have insurance coverage pathways tied to its FDA approval. Off-label IV or at-home ketamine is generally self-pay, with per-session costs that can run from roughly $400 to $800 at many U.S. clinics, so readers should get a full treatment-course estimate rather than a single session price before enrolling.

Where is this legal and available? State telehealth and prescribing rules for at-home ketamine have tightened in recent years, and availability varies by state, so readers should confirm a provider is licensed to prescribe in their state before assuming a telehealth option applies to them.

The bottom line for Ketamine Clinics Online readers: a patient saying ketamine worked better than years on Prozac is a real and encouraging data point, but it is not a green light to skip provider vetting. Confirm whether the treatment on offer is the FDA-approved esketamine pathway or an off-label ketamine protocol, then evaluate the clinic's screening, monitoring, and follow-up plan accordingly. Read the original New York Post report for the full patient accounts: Exclusive | FDA-approved ketamine treatment fights depression better than decades on Prozac, patients say.